Abstract: An embodiment rear side member of a vehicle includes a front portion extending forward in a vehicle length direction, a rear portion extending rearward in the vehicle length direction and disposed offset to an inside of the vehicle with respect to the front portion, and a transition portion in a curved shape connecting a rear end of the front portion and a front end of the rear portion and passing through both a first point configured to engage with a first arm of a first type suspension and a second point configured to engage with a second arm of a second type suspension different from the first type suspension.

Abstract: A pixel includes first, second, and third sub-pixels each including an emission area and a non-emission area. Each of the first, second, and third sub-includes a pixel circuit layer; a first electrode on the pixel circuit layer; a pixel defining layer on the first electrode and including an opening to expose an area of the first electrode; an emission layer on the pixel defining layer; a second electrode on the emission layer; a thin film encapsulation layer over the second electrode; a color filter on the thin film encapsulation layer; and an overcoat layer over the color filter. The overcoat layer has a refractive index greater than a refractive index of the color filter. A color filter of the second sub-pixel overlaps a color filter of each of the first and third sub-pixels in the non-emission area.

Abstract: A pore-filled ion exchange polyelectrolyte composite membrane from which the surface ion exchange polyelectrolyte has been removed and a method of manufacturing the same are provided. The ion exchange polyelectrolyte composite membrane exhibits low film resistance and low in-plane-direction swelling degree, and has a smaller film-thickness than a commercial film, and thus, can be used for various purposes. In addition, since the pore-filled ion exchange polyelectrolyte composite membrane is continuously manufactured through a roll-to-roll process, the manufacturing process is simple, and manufacturing costs can be greatly reduced.

Abstract: The present invention relates to a composition for preventing or treating transplantation rejection or a transplantation rejection disease, comprising a novel compound and a calcineurin inhibitor. A co-administration of the present invention 1) reduces the activity of pathogenic Th1 cells or Th17 cells, 2) increases the activity of Treg cells, 3) has an inhibitory effect against side effects, such as tissue damage, occurring in the sole administration thereof, 4) inhibits various pathogenic pathways, 5) inhibits the cell death of inflammatory cells, and 6) increases the activity of mitochondria, in an in vivo or in vitro allogenic model, a transplantation rejection disease model, a skin transplantation model, and a liver-transplanted patient, and thus inhibits transplantation rejection along with mitigating side effects possibly occurring in the administration of a conventional immunosuppressant alone.

Abstract: An inductor includes a first magnetic body having a toroidal shape and having a ferrite; and a second magnetic body configured to be different from the first magnetic body and including a metal ribbon, wherein the second magnetic body includes an outer magnetic body disposed on an outer circumferential surface of the first magnetic body and an inner magnetic body disposed on an inner circumferential surface of the first magnetic body, and each of the outer magnetic body and inner magnetic body is wound in a plurality of layers in a circumferential direction of the first magnetic body.

Abstract: The present invention relates to a compound capable of lowering the flammability of a non-aqueous electrolyte when included in the non-aqueous electrolyte and improving the life properties of a battery by forming an electrode-electrolyte interface which is stable at high temperatures and low in resistance, and relates to a compound represented by Formula I descried herein, a non-aqueous electrolyte solution and a lithium secondary battery both including the compound, n, m, Ak, and X are described herein.

Abstract: A frame structure for a vehicle includes: an inner panel connected to a side member and defining an inner side of a rear part of the side member; an outer panel connected to a rear side of the side member and coupled to an outer side of the inner panel defining a closed cross-section together with the inner panel and defining an outer side of the rear part of the side member; an opening portion formed below the inner and outer panels partially opening the closed cross-section so that a front end of a rear suspension arm can be inserted into the opening portion; and a reinforcing member disposed in the opening portion defining the closed cross-section together with the outer panel and the inner panel and configured to close an internal space in the outer and inner panels.

Abstract: A packaging device including bumps and a method of manufacturing the packaging device are presented. In the method of manufacturing a packaging device, a dielectric layer that covers a packaging base is formed and a lower layer is formed over a packaging base including first and second connecting pads. A plurality of dummy bumps that overlaps with the dielectric layer is formed. A sealing pattern that covers the dummy bumps, filling areas between the dummy bumps, is formed. A lower layer pattern in which the plurality of dummy bumps have been disposed is formed by removing portions of the lower layer that are exposed and do not overlap with the sealing pattern.

Abstract: The present disclosure relates to an ultraviolet light-blocking composition containing a centipede grass extract and a cosmetic composition and, more specifically, to an ultraviolet light-blocking composition comprising a centipede grass (Eremochloa ophiuroides) leaf extract as an active ingredient; and a cosmetic composition containing the ultraviolet light-blocking composition.

Abstract: Disclosed is a lamp module for an industrial vehicle. The lamp module for an industrial vehicle according to an embodiment of the present utility model can be installed inside a counterweight, unlike the conventional method of embedding in the counterweight, thereby improving workability and assemblability of the operator and improving visibility.

Abstract: The present invention relates to a method of inducing neuro-regeneration comprising administering a MEK 1/2 inhibitor to a patient in need thereof. In the present invention, the MEK1/2 inhibitor induces neuro-regeneration by differentiating neural stem cells into neurons, by protecting neural stem cells and neurons against cytotoxicity of amyloid-betas, or by both of the above. Also, the present invention relates to a method of protecting neurons against neuronal loss or damage comprising administering a MEK 1/2 inhibitor. In addition, this invention relates to a method of preventing or treating neurodegenerative disease due to neuronal loss or damage for patients in need thereof comprising administering a MEK 1/2 inhibitor.

Abstract: The present invention relates to: a method for evaluating response to treatment using a MEK 1/2 inhibitor in an individual diagnosed with a neurodegenerative disease; and a composition to be used for the method. Particularly, the method of the present invention comprises measuring, in a biological sample obtained from the individual with a neurodegenerative disease, the concentration of at least one biomarker selected from the group consisting of osteopontin, synaptotagmin-1, apolipoprotein-E, cathepsin B, HLA-DOB (HLA class II histocompatibility antigen, DO beta chain), and neurofilament light chain. According to the present invention, response to the MEK 1/2 inhibitor in the individual diagnosed with a neurodegenerative disease is monitored, and it is thereby possible to obtain useful information for managing the individual, such as determining the possibility of a treatment effect early on and determining whether to continue drug treatment and whether the amount needs to be adjusted.

Abstract: Disclosed is a lamp module for an industrial vehicle. The lamp module for an industrial vehicle according to an embodiment of the present utility model can be installed inside a counterweight, unlike the conventional method of embedding in the counterweight, thereby improving workability and assembility of the operator and improving visibility.

Abstract: The present invention relates to administration methods and dosage regimens for treatment of neurodegenerative diseases using trametinib and markers. The administration methods and dosage regimens induce neural regeneration and changes in gene expression.

Abstract: The present invention relates to a method of inducing neuro-regeneration comprising administering a MEK 1/2 inhibitor to a patient in need thereof. In the present invention, the MEK1/2 inhibitor induces neuro-regeneration by differentiating neural stem cells into neurons, by protecting neural stem cells and neurons against cytotoxicity of amyloid-betas, or by both of the above. Also, the present invention relates to a method of protecting neurons against neuronal loss or damage comprising administering a MEK 1/2 inhibitor. In addition, this invention relates to a method of preventing or treating neurodegenerative disease due to neuronal loss or damage for patients in need thereof comprising administering a MEK 1/2 inhibitor.

Abstract: The present invention relates to a method of inducing neuro-regeneration comprising administering a MEK 1/2 inhibitor to a patient in need thereof. In the present invention, the MEK1/2 inhibitor induces neuro-regeneration by differentiating neural stem cells into neurons, by protecting neural stem cells and neurons against cytotoxicity of amyloid-betas, or by both of the above. Also, the present invention relates to a method of protecting neurons against neuronal loss or damage comprising administering a MEK1/2 inhibitor. In addition, this invention relates to a method of preventing or treating neurodegenerative disease due to neuronal loss or damage for patients in need thereof comprising administering a MEK 1/2 inhibitor.

Abstract: The present invention relates to administration methods and dosage regimens for treatment of neurodegenerative diseases, in particular ALS, using trametinib. The administration methods and dosage regimens induce neural regeneration and changes in gene expression.

Abstract: The present invention relates to a method of inducing neuro-regeneration comprising administering a MEK 1/2 inhibitor to a patient in need thereof. In the present invention, the MEK1/2 inhibitor induces neuro-regeneration by differentiating neural stem cells into neurons, by protecting neural stem cells and neurons against cytotoxicity of amyloid-betas, or by both of the above. Also, the present invention relates to a method of protecting neurons against neuronal loss or damage comprising administering a MEK1/2 inhibitor. In addition, this invention relates to a method of preventing or treating neurodegenerative disease due to neuronal loss or damage for patients in need thereof comprising administering a MEK 1/2 inhibitor.

Abstract: A modularization of a circulator and a directional coupler used in a wireless communication system comprises: a circulator; and a signal coupler, where the signal coupler does not have directivity by itself, and directivity of the circulator module is controlled by isolation characteristics of the circulator to improve electrical characteristics of a wireless communication system and miniaturize the wireless communication system by applying the electrical characteristics in common with a circulator to modularize the wireless communication system without implementation of a circuit of a directional coupler capable of sampling high-frequency signals.

Abstract: The present invention relates to a method of inducing neuro-regeneration comprising administering a MEK 1/2 inhibitor to a patient in need thereof. In the present invention, the MEK1/2 inhibitor induces neuro-regeneration by differentiating neural stem cells into neurons, by protecting neural stem cells and neurons against cytotoxicity of amyloid-betas, or by both of the above. Also, the present invention relates to a method of protecting neurons against neuronal loss or damage comprising administering a MEK1/2 inhibitor. In addition, this invention relates to a method of preventing or treating neurodegenerative disease due to neuronal loss or damage for patients in need thereof comprising administering a MEK 1/2 inhibitor.